Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
Citi analyst Jamie Wang double upgraded IPG Photonics (IPGP) to Buy from Sell with a price target of $105, up...
Pakistan’s Shehbaz Sharif government is preparing to table the 27th Constitutional Amendment in Parliament, a proposal that could give more...
When Ozempic and Wegovy launched, their bombshell success was only going to be exclusive to their maker—Novo Nordisk—for a matter...
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking...
Bitcoin has been falling again — but unlike in last month’s selloff, it’s not leverage breaking the market.The original cryptocurrency...
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
